MCM Vaccine B.V. is a European joint venture formed between Sanofi Pasteur Inc. and Merck & Co., Inc. (known as MSD outside US and Canada). The partnership combines innovation and expertise to offer an hexavalent pediatric vaccine.
MCM Vaccine B.V. (in Europe) and MSP (in the US) were established in 1991 to enable MSD and Sanofi Pasteur to co-develop an hexavalent pediatric vaccine that can combine and deploy the proven antigens developed by each company.
MSD and Sanofi Pasteur are two of the world’s largest vaccine companies, both with long track records in vaccine and antigen development. They have collaborated for more than 30 years in the US, Europe and Australia, allowing them to pool their extensive experience in developing, manufacturing and marketing combination vaccines.